Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

The path to now: How did the current management of advanced urothelial carcinoma develop?

Date

27 Sep 2019

Session

Janssen Pharmaceutical Companies of Johnson & Johnson - Integrating precision medicine: Are we ready for a paradigm shift in advanced urothelial carcinoma?

Presenters

Shahrokh F. Shariat

Authors

S.F. Shariat

Author affiliations

  • Urology, Medizinische Universitaet Wien, 1090 - Vienna/AT
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings